Atlas Trials

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

Clinical trial NCT05891548 · COMPLETED

Trial details

NCT number
NCT05891548
Sponsor
Clearside Biomedical, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2023-05-31
Primary completion
2024-08-20
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.